Type your tag names separated by a space and hit enter

trimebutine

General

Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.

Pronunciation:
try-meh-boo-teen

Trade Name(s)

  • Modulon Canadian Tradename

Ther. Class.
lower gastrointestinal tract motility regulators
spasmolytics

Indications

  • Symptomatic treatment of irritable bowel syndrome (IBS).
  • Treatment of postoperative paralytic ileus.

Action

Acts as a spasmolytic.

Therapeutic Effect(s):

  • ↓ symptoms of IBS.
  • Resumption of intestinal transit following abdominal surgical procedures.

Pharmacokinetics

Absorption: Rapidly absorbed following oral administration.

Distribution: Unknown.

Metabolism and Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.

Half-life: 2.7–3.1 hr.

TIME/ACTION PROFILE (symptom relief)

ROUTEONSETPEAKDURATION
POwithin 3 days–2 wk1 hr (blood level)>1 wk (following discontuation)

Contraindication/Precautions

Contraindicated in:

  • Hypersensitivity.

Use Cautiously in:

  • OB: Not recommended for use;
  • Pedi: Children <12 yr (safety and effectiveness not established).

Adverse Reactions/Side Effects

CNS: dizziness, drowsiness, fatigue, headache

GI: diarrhea, dry mouth, dysguesia, dyspepsia, epigastric pain, nausea

Derm: hot/cold sensation, rash

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None known

Route/Dosage

PO: (Adults) 200 mg 3 times daily.

Availability

Tablets: 100 mg, 200 mg

Assessment

  • Assess for symptoms of irritable bowel syndrome (cramping, constipation and diarrhea, mucus in stools).
  • Assess for abdominal distention and assess bowel sounds.
  • Monitor intake and output and record.

Potential Diagnoses

  • Acute pain
  • Diarrhea

Implementation

  • PO: Administer three times daily before meals.

Patient/Family Teaching

  • Instruct patient to take trimebutine as directed.
  • Advise female patient to inform health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Decrease signs and symptoms of irritable bowel disease.

trimebutine is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.

Citation

Quiring, Courtney, et al. "Trimebutine." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109872/all/trimebutine.
Quiring C, Sanoski CA, Vallerand AH. Trimebutine. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109872/all/trimebutine. Accessed April 21, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Trimebutine. In Davis's Drug Guide. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109872/all/trimebutine
Quiring C, Sanoski CA, Vallerand AH. Trimebutine [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 21]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109872/all/trimebutine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - trimebutine ID - 109872 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109872/all/trimebutine PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -